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lethal GVHD while maintaining GVL activity after BMT with
allogeneic naive (uncultured) thymidine kinase (TK)-expressing
transgenic T cells. However, the efﬁcacy of GCV control of
GVHD and its impact on GVL activity following BMT with ex
vivo activated, TK transduced and selected (Td) donor T cells has
not been thoroughly characterized because of the signiﬁcantly
reduced GVHD-inducing potential of cultured cells compared to
naive T cells in both preclinical models and initial clinical trials. In
these experiments, we used A20 tumor cells (B cell lymphoma of
BALB/c origin) that were modiﬁed to stably express a click beetle
red luciferase-EGFP fusion reporter gene (A20-CBRluc/egfp) and
monitored disease progression in vivo using optical biolumines-
cence imaging (BLI). To induce leukemia, BALB/c recipients were
lethally irradiated and reconstituted with C57BL/6 BM supple-
mented with or without A20-CBRluc/egfp leukemia cells. Mice
receiving leukemia cells were then left untreated or injected with
4  106 CD34-TK (chimeric fusion suicide gene) Td donor T
cells the day of BMT. Ten of ten BALB/c mice transplanted with
BM and A20-CBRluc/egfp cells exhibited tumor engraftment and
growth, with 8 mice dying from leukemia before day 35. In con-
trast, we observed no signiﬁcant tumor signal in the majority (92%)
of untreated (No GCV) mice that received CD34-TK Td T cells.
However, these animals developed GVHD with high mortality
(P  .003 compared to BM only control) and signiﬁcant weight
loss (P  .05 from day 10 onward compared to BM only control).
Although mice treated with GCV from days 4–10 after BMT were
protected from GVHD, 50% of these animals developed leukemia.
In contrast, none of the mice developed leukemia if GCV treat-
ment was delayed until day 10 after BMT. Importantly, this GVL
effect was obtained in the absence of GVHD, as evidenced by the
improved survival (88% survival at day 60 post-BMT) and weight
gain of the day 10–16 GCV treated mice compared to the un-
treated (No GCV) control. These data suggest that donor T cell
dependent GVL effects against A20 cells can be preserved while
the severity of GVHD is reduced, further demonstrating the po-
tential of the HSV-TK/GCV system to reduce acute GVHD
without impairing GVL activity.
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“MINI” METHOTREXATE AND FK506 AS GVHD PROPHYLAXIS IN PE-
DIATRIC UMBILICAL CORD BLOOD TRANSPLANTATION
Staba, S.L., Hunger, S.P., Wingard, J.R. University of Florida,
Gainesville, FL.
A majority of umbilical cord blood transplants to date utilize
steroids and cyclosporine for graft-versus-host disease (GVHD)
prophylaxis. Steroids are associated with multiple complications
including hyperglycemia, hypertension, avascular necrosis/osteo-
porosis, and signiﬁcant risk of infection. In an effort to decrease the
adverse effects of GVHD prophylaxis, we chose an alternative
combination of “mini” methotrexate (5 mg/m2  4 doses) and
FK506. Here we report our experience with this GVHD prophy-
laxis regimen. Ten children (ages 4 months to 13 years) underwent
umbilical cord blood transplant at the University of Florida be-
tween June 2004 and June 2005. All patients received a cord blood
unit that was matched at 6/6 (n  4), 5/6 (n  2), or 4/6 (n  4)
HLA loci. Children with malignant disease received either Cyclo-
phosphamide/TBI or Etoposide/TBI as the preparative regimen,
while children with non-malignant disease received Busulfan, Cy-
clophosphamide, and ATG. Umbilical cord blood cell dose ranged
from 3.4–23.7 (median 7.8)  107nucleated cells/kg. All children
received Methotrexate 5 mg/m2 on days 1, 3, 6, and 11, with
Leucovorin on days 4, 7, and 12. No doses of Methotrexate were
held. FK506 was started as a continuous infusion at day 3,
targeting levels of 10–15. The FK506 was changed to twice daily
oral dosing when tolerated. Results: 8 of the 10 children en-
grafted, with engraftment occurring at a median of 15 (range
13–38) days post transplant. Rates of acute and chronic GVHD
were low, with no grade III or IV acute GVHD seen, and no
extensive chronic GVHD occurring. Two children had grade II
acute GVHD (skin and GI). Two children developed limited
chronic GVHD of the skin while weaning FK506. GHVD resolved
completely in these patients with an increase in FK506 and were
subsequently were weaned off immunosuppression. Mucositis was
very similar to other GVHD regimens. One child became CMV
PCR positive, with CMV on bronchoscopy, however had mild
disease (never required oxygen) and recovered completely. There
were otherwise no serious infections in this patient population
beyond the time of engraftment. FK506 and “mini” Methotrexate
for GVHD prophylaxis in pediatric patients undergoing umbilical
cord blood transplant is well tolerated. Engraftment was not de-
layed and mucositis was not severe. Low rates of GHVD were seen
with minimal serious infections, making this an attractive option
for GVHD prophylaxis.
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It has been suggested that adult human mesenchymal stem cells
(hMSCs) have a potential to treat graft-versus-host Disease
(GVHD). At the present time, Osiris Therapeutics is in clinical
development with ProchymalTM, a cellular therapy consisting of
allogeneic bone marrow derived adult hMSCs for the treatment of
acute gastrointestinal GVHD. The present work reports a success-
ful treatment of an 8-month-old infant with grade III skin and gut
GVHD using ProchymalTM. The infant was born with hypocal-
cemia with normal phosphorus and carbonic anhydrase II, and
elevated PTH. Skeletal survey and bone marrow biopsy were
consistent with osteopetrosis. The infant received a 4/6 unrelated
cord blood transplant after standard Busulfan/Cyclophosphamide/
ATG conditioning. The ﬁrst graft failed and the patient developed
autologous reconstitution. A second transplant (4 of 6 matched
cord blood) was given at 5 months of life after Fludaribine/Cyclo-
phosphamide/ATG conditioning regimen. The patient developed
severe acute grade III skin GVHD with gastrointestinal involve-
ment in the form of bloody diarrhea that was resistant to high dose
steroids, Tacrolimus, Cellcept, and anti-CD25 antibody. A com-
passionate use protocol was developed for the treatment of the
patient with ProchymalTM. Two intravenous infusions of Prochy-
malTM were given at a dose of 8  106 cells/kg body weight each
3 days apart starting on day 100 post transplant. Both infusions
were well tolerated with no associated toxicity or reaction. By the
fourth day of treatment, there were initial signs of improvement of
the skin. By day 7, the skin improvement was dramatic and epi-
sodes of diarrhea had ceased. By day 14, the resolution of this
patient’s refractory GVHD was essentially complete. Grade IV
skin GVHD recurred approximately 1 month following initial
treatment after weaning of immune suppression. Repeat treatment
with ProchymalTM was administered starting on day 120 post
transplant and GVHD symptoms diminished within 1 week. The
patient developed 100% donor chimerism. The patient’s myeloid
engrafted improved from 8% on day 105 post transplant to 100%
by day 145. Data suggest that MSCs suppressed the adverse im-
munological response, healed damaged skin and gut tissue, and
aided in engraftment. We conclude that ProchymalTM may be
clinically useful for treatment of refractory cases of GVHD.
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FUL MARKER OF ACUTE GRAFT-VERSUS HOST DISEASE AFTER HLA-
HAPLOIDENTICAL BONE MARROW TRANSPLANTATION
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